The Effect of Longer-Acting vs Shorter-Acting Testosterone Therapy on Follicle Stimulating Hormone and Luteinizing Hormone.

Follicle-Stimulating Hormone Gonadotropins Luteinizing Hormone Testosterone

Journal

Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773

Informations de publication

Date de publication:
01 2021
Historique:
received: 27 04 2020
revised: 20 07 2020
accepted: 24 07 2020
pubmed: 12 9 2020
medline: 15 12 2021
entrez: 11 9 2020
Statut: ppublish

Résumé

Testosterone (T) replacement therapy causes suppression of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that can lead to decrease in semen parameters and possible infertility. Different T formulations may have varying suppression on FSH and LH. To study whether shorter-acting T (multiple daily dosing) has less suppression on FSH and LH serum levels compared with longer-acting T (transdermal gel, injectable). A systematic literature search was conducted by following the protocol based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis protocols. We comprehensively reviewed the literature by systematically searching manuscripts indexed in PubMed from 1995 to March 13, 2019 to identify studies reporting changes in FSH and LH in hypogonadal men treated with exogenous T which evaluated the effect of exogenous T on FSH and LH. A total of 8 studies reported the effect of T on FSH and LH in 793 hypogonadal men: 2 used long-acting injectables (enanthate or undecanoate) in a total of 16 men, 5 used intermediate-acting daily topical gels or patches in a total of 471 men, and 1 used short-acting intranasal T (125 μL/nostril, twice a day or three times a day) in 306 men. Long-acting injectables decreased FSH by 86.3%, intermediate-acting daily gels/patches decreased FSH by 60.2%, and short-acting intranasal gel decreased FSH by 37.8%. Long-acting injectables decreased LH by 71.8%, intermediate-acting daily gels/patches decreased LH by 59.2%, and short-acting intranasal gel decreased LH by 47.3%. Our findings suggest that short-acting T preparations do not decrease serum FSH or LH to the same extent as longer-acting transdermal gels and injectables. However, further clinical trial data are necessary to determine whether the effect of short-acting TRT on gonadotropins translates into similar changes in semen parameters and fertility. Masterson TA, Turner D, Vo D, et al. The Effect of Longer-Acting vs Shorter-Acting Testosterone Therapy on Follicle Stimulating Hormone and Luteinizing Hormone. Sex Med Rev 2021;9:143-148.

Identifiants

pubmed: 32912767
pii: S2050-0521(20)30076-7
doi: 10.1016/j.sxmr.2020.07.006
pii:
doi:

Substances chimiques

Testosterone 3XMK78S47O
Luteinizing Hormone 9002-67-9
Follicle Stimulating Hormone 9002-68-0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-148

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Thomas A Masterson (TA)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Darren Turner (D)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Duyen Vo (D)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Ruben Blachman-Braun (R)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Jordan C Best (JC)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Gerwin Westfield (G)

Aytu Biosciences, Denver, CO, USA.

Nathan Bryson (N)

Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada.

Ranjith Ramasamy (R)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: ramasamy@miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH